Lisata Therapeutics, Inc.LSTANASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank29
Studio
Year-over-Year Change

Year-over-year research & development expense growth

Percentile
P29
Within normal range
vs 3Y Ago
-0.2x
Contraction
Streak
1 yr
Consecutive declineDecelerating
PeriodValue
2025-29.87%
2024-10.99%
2023-70.70%
2022147.27%
202189.95%
2020-31.44%
201977.73%
2018-55.70%
201713.46%
2016-36.78%